- 1. Secure our presence in the generics business.
- 2. Achieve a stronger position in the hyperuricemia market, centered on Uralyt.
- 3. Contribute to society through proprietary developments toward drug discovery.
The goal of the Chemiphar Group is to make a difference in society by providing pharmaceutical drugs and health-related services to help people become and remain healthy.
December 14, 2020 | |
---|---|
November 18, 2020 | Highlights of Second Quarter FY2020 Business Results. (pdf, 714KB) |
October 30, 2020 | Chemiphar announced second quarter business summary FY2020. (pdf, 292KB) |
September 18, 2020 | Chemiphar announced Results of early retirement package. (pdf, 167KB) |
September 07, 2020 | |
August 24, 2020 | Chemiphar announced capital and business tie-up with SUSMED (pdf, 143KB) |
July 31, 2020 | |
July 22, 2020 | Notice of structural reforms to the Nippon Chemiphar Group. (pdf,106KB) |
May 22, 2020 | |
---|---|
May 18, 2020 |